Business Standard

Covid-19: Gilead drug data lifts hopes, Fauci calls it 'highly significant'

President Donald Trump during a White House meeting greeted Gilead's reports as good news

Healthcare workers take a swab sample of a commuter-train worker during a test amid the coronavirus disease (COVID-19) outbreak, in Bogor, West Java province, Indonesia. Photo: Reuters
Premium

Healthcare workers take a swab sample of a commuter-train worker during a test amid the coronavirus disease (COVID-19) outbreak, in Bogor, West Java province, Indonesia. Photo: Reuters

Deena Beasley and Manas Mishra | Reuters
A top U.S. health official said Gilead Sciences Inc's experimental antiviral drug remdesivir is likely to become the standard of care for COVID-19 after early results from a key clinical trial on Wednesday showed it helped certain patients recover more quickly from the illness caused by the coronavirus.

Preliminary results from a U.S. government trial show that patients given remdesivir had a 31% faster recovery time than those who received a placebo, results hailed by Dr. Anthony Fauci, the nation's top infectious disease expert, as "highly significant."

Gilead earlier on Wednesday said remdesivir helped improve outcomes for patients with COVID-19 in the

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Apr 30 2020 | 12:02 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com